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Background and Aims {#jdi13043-sec-0001}
===================

Many databases have been developed to store and generate information about diabetes mellitus and other chronic diseases[1](#jdi13043-bib-0001){ref-type="ref"}, [2](#jdi13043-bib-0002){ref-type="ref"}, but their subsequent use can be limited by inconsistent data standards, such as the precise sets of data items used, and they may therefore have limited utility beyond their initially defined roles. Recently, there has been a rapid expansion of digitization in clinical practice and research. When appropriate information standards are defined before a new database is created, it may then be possible to reuse the database for other purposes. For example, a database developed for tracking information about patient self‐monitoring of diabetes might then be used for clinical research, establishing evidence‐based quality indicators, or facilitating regional medical cooperation.

In 2010, the Japan Diabetes Society (JDS) and the Japan Association for Medical Informatics (JAMI) established the Collaborative Committee for Clinical Informatization in Diabetes Mellitus (CCCIDM) to review the digitalization of clinical data about diabetes mellitus. The present article is a report of the work of the committee in collaboration with six Japanese academic associations: the JDS and JAMI, as well as the Japanese Society of Hypertension (JSH), the Japan Atherosclerosis Society (JAS), the Japanese Society of Nephrology (JSN), and the Japanese Society of Laboratory Medicine (JSLM, which participated from 2015). The report introduces the sets of data items established by the committee in 2015 for diabetes mellitus and the associated chronic diseases hypertension, dyslipidemia, and chronic kidney disease (CKD), as well as the committee\'s recommended data configurations, established in August 2018, for personal health record (PHR) applications, which was the first use of the data sets.

Materials and Methods {#jdi13043-sec-0002}
=====================

By the end of 2011, CCCIDM developed a core data item set (CIS) that listed the minimum set of data items necessary for diabetes‐related databases. However, the CIS alone could not be used in databases without additional data items. CCCIDM therefore proposed a self‐management item set (SMIS), which may be useful for disease management by diabetic patients themselves based on the CIS developed by a working group sponsored by the Japanese Cabinet Secretariat and chaired by Professor Emeritus Naoko Tajima of Jikei University School of Medicine, who was also the first chairperson of the CCCIDM. Two other members of the CCCIDM also participated in the working group. The SMIS for diabetes was approved by the working group in 2012 and was subsequently approved by CCCIDM.

Because patients with diabetes often have other chronic diseases, it can be useful to combine data about diabetes mellitus with data about other chronic diseases. Therefore, in addition to diabetes mellitus, CCCIDM selected hypertension, dyslipidemia, and CKD for consideration because (i) they are associated with high rates of morbidity, (ii) they are associated with considerable personal and socioeconomic burdens, (iii) they are preventable through patient self‐management, and (iv) they can be evaluated and monitored using clear clinical parameters, such as blood testing and lifestyle monitoring. After selecting these diseases, CCCIDM invited the Japanese academic associations for each disease (JSH, JAS, and JSN) to form a collaborative extended committee (CEC) to establish consistent overlapping data item sets for all four diseases with the support of the Japanese Cabinet Secretariat. The SMISs for hypertension, dyslipidemia, and CKD were established in combination with the CISs in 2014 and were subsequently published on JAMI\'s website[3](#jdi13043-bib-0003){ref-type="ref"}. The CIS and SMIS for each disease were standardized in terms of data item name, granularity, and expression or unit used.

In 2015, the JSLM was included in the CEC. Since 2016, the CEC has collaborated with a PHR project entitled 'Research on standardization and establishment of a business model for preventing the aggravation of lifestyle‐related diseases, in cooperation with medical insurers, disease management companies, and medical institutions,\' administered by the Medical Information System Development Center (MEDIS‐DC) and sponsored by the Japan Agency for Medical Research and Development (AMED). The aim of that project was to develop SMISs for implementation in PHR applications by mapping them to version 10 of the Japan Laboratory Analysis Codes (JLAC10)[4](#jdi13043-bib-0004){ref-type="ref"}. These codes are the Japanese standard for laboratory testing and can be mapped to logical observation identifier names and codes, which are international common terms (a set of identifiers, names, and codes) for identifying health measurements, observations, and documents[5](#jdi13043-bib-0005){ref-type="ref"}. The CEC subsequently determined the boundary values and thresholds for risk stratification, as well as values that could be used to provide smartphone alerts to various users, including patients, family members, and medical staff, based on standard clinical guidelines for the chronic diseases. The CEC also identified parameters that could be used to avoid data input errors and to prompt users to input data into the PHR within the appropriate time interval for each item.

Results {#jdi13043-sec-0003}
=======

Between 2011 and 2014, the CEC established CISs and SMISs that included the CISs for each of the four chronic diseases and revised them in 2018 (Figures [1](#jdi13043-fig-0001){ref-type="fig"} and [2](#jdi13043-fig-0002){ref-type="fig"}). The CISs comprised 14 items for diabetes mellitus, 13 for hypertension, 13 for dyslipidemia, and 12 for CKD. By eliminating overlapping items, the overall number of CIS items was reduced from 52 to 23 (Figure [2](#jdi13043-fig-0002){ref-type="fig"}). The SMISs comprised 22 items for diabetes mellitus, 18 for hypertension, 15 for dyslipidemia, and 23 for CKD. After eliminating overlapping items, the total number of SMIS items was reduced from 78 to 41 (Figure [2](#jdi13043-fig-0002){ref-type="fig"}).

![Core item sets for diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease[3](#jdi13043-bib-0003){ref-type="ref"}.](JDI-10-868-g001){#jdi13043-fig-0001}

![The self‐management item sets[3](#jdi13043-bib-0003){ref-type="ref"}. Notes: (\*1) Regular visits to a dental clinic (at least once per year). (\*2) A family history of renal failure, including hemodialysis, renal transplantation, or renal failure in a family member of ≤2 degrees of separation](JDI-10-868-g002){#jdi13043-fig-0002}

The four CISs and four SMISs were approved by the administrative boards of all six associations in 2015 (the first edition) and in 2018 (the second edition). During 2016 and in August 2018, the CEC developed detailed specifications (Tables [S1](#jdi13043-sup-0004){ref-type="supplementary-material"} to [S6](#jdi13043-sup-0006){ref-type="supplementary-material"}) for implementing the four SMISs in PHR applications, described as 'recommended configurations for the PHRs of chronic diseases.\' This was performed in collaboration with a PHR project by MEDIS‐DC.

Because the standard clinical guidelines ask stricter indicators for patients with chronic diseases than for healthy people, the CEC determined a basic configuration for healthy people (Table [S1](#jdi13043-sup-0001){ref-type="supplementary-material"}) and associated configurations for diabetes mellitus (Table [S2](#jdi13043-sup-0002){ref-type="supplementary-material"}), hypertension (Table [S3](#jdi13043-sup-0003){ref-type="supplementary-material"}), dyslipidemia (Table [S4](#jdi13043-sup-0004){ref-type="supplementary-material"}), CKD (Table [S5](#jdi13043-sup-0005){ref-type="supplementary-material"}), and coronary heart disease (Table [S6](#jdi13043-sup-0006){ref-type="supplementary-material"}), which were added during a discussion by the CEC for risk assessment of the four chronic diseases. The tables show the various strict values for reminders, alerts, or thresholds for risk stratifications. PHR applications should use the basic configuration (Table [S1](#jdi13043-sup-0001){ref-type="supplementary-material"}) to detect possibility of pre‐diseases (yellow) or the onset of diseases (orange and red) when the user does not have any previously diagnosed disease. And the additional configuration for the appropriate chronic disease to know the risk of serious complications of the diseases (green; minimum risk, yellow; light risk, orange; moderate risk, red; high risk) when the patient experiences the onset of the disease (Table [S2](#jdi13043-sup-0002){ref-type="supplementary-material"} to [S6](#jdi13043-sup-0006){ref-type="supplementary-material"}). If the PHR has various configurations because the patient suffers from more than one of the chronic diseases, the strictest configuration should be used.

The CEC defined fasting and non‐fasting conditions for the configuration of PHRs for chronic diseases. The fasting condition follows fasting for 10 h (although the consumption of water and non‐calorie tea are acceptable). The values for alerts and risk stratification in the configuration of the PHR refer to fasting condition results for the tests for blood glucose (SMIS‐ID 10 in Figure [2](#jdi13043-fig-0002){ref-type="fig"}), triglycerides (SMIS‐ID 18), urine glucose (SMIS‐ID 28), and self‐monitored blood glucose (no ID). The CEC recommends that PHR applications include a function to identify whether these four items have been measured under the fasting condition.

The SMIS and recommended PHR configuration have several lipid‐related indicators, including levels of low‐density lipoprotein (LDL) cholesterol (by direct assay), total cholesterol, high‐density lipoprotein (HDL) cholesterol, and triglycerides. Additional indicators, such as LDL cholesterol by the Friedewald formula and non‐HDL cholesterol, can be calculated from data in the SMIS. However, serum triglyceride levels are affected by eating, and some indicators are unstable in blood samples with high triglyceride levels. Thus, the JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017[6](#jdi13043-bib-0006){ref-type="ref"} has specified the following according to triglyceride levels: when the triglyceride level is \<400 mg/dL, LDL cholesterol by the Friedewald formula (only in the fasting condition) or direct assay, or non‐HDL‐cholesterol, should be used for the evaluation; when the triglyceride level is in the range 400--600 mg/dL, LDL cholesterol (by direct assay but not by the Friedewald formula) or non‐HDL‐cholesterol should be used for the evaluation; for triglyceride levels in the range 600--1,000 mg/dL, LDL cholesterol by direct assay, but not by the Friedewald formula, should be used for the evaluation; and when triglycerides ≥1,000 mg/dL, triglyceride should be improved before the evaluation of lipid‐related indicators.

The JSLM subsequently mapped the SMISs to the JLAC10 (Table [1](#jdi13043-tbl-0001){ref-type="table"}), and this map was approved by the CEC in 2018. Mapping the SMISs to JLAC10 is complicated because it depends on factors, such as the assay methods and reagents used. Therefore, when PHR providers install actual JLAC10 codes in the system, they should be careful and ensure they use the correct codes.

###### 

Mapping similarities between the self‐management item set and the Japan Laboratory Analysis Code version 10 (JLAC10)

  Number        Item name                            Expression/unit                                                JLAC10 code                                                                                                                                                                       Supplement
  ------------- ------------------------------------ -------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  1             Hight                                cm                                                             9N001000000000001                                                                                                                                                                 
  2             Weight                               kg                                                             9N006000000000001                                                                                                                                                                 
  3             Systolic blood pressure              mmHg                                                           9A751000000000001                                                                                                                                                                 
  4             Diastolic blood pressure             mmHg                                                           9A761000000000001                                                                                                                                                                 
  5             LDL‐cholesterol                      mg/dL                                                          3F077000002327101                                                                                                                                                                 
                                                                                                                    3F077000002391901                                                                                                                                                                 Friedewald
  6             HDL cholesterol                      mg/dL                                                          3F070000002327101                                                                                                                                                                 
  7             Smoking                              Yes, No, Yes in the past                                       9N736000000000011                                                                                                                                                                 
  8             Serum creatinin                      mg/dL                                                          3C015000002327101                                                                                                                                                                 
  9             Urine protein                        ‐, ±,+, 2+, 3+or over                                          1A990000000190153                                                                                                                                                                 Urinary test strip method
  10            Blood glucose                        mg/dL                                                          3D010\*\*\*\*01927201                                                                                                                                                             NaF,Plasma
                                                                                                                    \*\*\*\* \[1,288: before breakfast, 1,289: after breakfast, 1,290: before lunch, 1,291: after lunch, 1,292: before supper, 1,293: after supper, 1,299: casual, 1,300: fasting\]   
  11            Age diagnosed as diabetes mellitus   Less than 10y.o, 10s, 20s, 70s, 80 y.o or over, Unknown        9N041000000000011                                                                                                                                                                 
  12            HbA1c (NGSP)                         \%                                                             3D046000001920402                                                                                                                                                                 
  13            ALT                                  IU/L                                                           3B045000002327201                                                                                                                                                                 
  14            Diabetic retinopathy                 Yes, No, Unknow                                                9N042000000000011                                                                                                                                                                 
  15            Age diagnosed as hypertension        Less than 10y.o, 10s, 20s, 70s, 80 y.o or over, Unknown        9N043000000000011                                                                                                                                                                 
  16            Serum potacium                       mEq/L                                                          3H015000002326101                                                                                                                                                                 
  17            Abnormality on ECG                   Yes, No, Unknow                                                9A110160700000011                                                                                                                                                                 
  18            Trigriceride                         mg/dL                                                          3F0150\*\*\*\*2327101                                                                                                                                                             
                                                                                                                    \*\*\*\* \[1,288: before breakfast, 1,289: after breakfast, 1,290: before lunch, 1,291: after lunch, 1,292: before supper, 1,293: after supper, 1,299: casual, 1,300: fasting\]   
  19            Age diagnosed as dyslipidemia        Less than 10y.o, 10s, 20s, 70s, 80 y.o or over, Unknown        9N044000000000011                                                                                                                                                                 
  20            Past history of coronary diseases    Yes (by contrast study), Yes (by another study), No, Unknown   9N721000000000011                                                                                                                                                                 
  21            Age diagnosed as CKD                 Less than 10y.o, 10s, 20s, 70s, 80 y.o or over, Unknown        9N045000000000011                                                                                                                                                                 
  22            Serum albumin                        g/dL                                                           3A015000002327101                                                                                                                                                                 
  23            Hematuria                            ‐, ±,+, 2+, 3+or over (Micro hematuria), Macrohematuria        1A990000000190159                                                                                                                                                                 Urinary test strip method
  24            Total cholesterol                    mg/dL                                                          3F050000002327101                                                                                                                                                                 
                Non‐HDL‐cholesterol                  mg/dL                                                          3F069000002391901                                                                                                                                                                 
  25            Urine albumin/Creatinin              mg/gCr                                                         3A015000000106128                                                                                                                                                                 
  26            AST                                  IU/L                                                           3B035000002327201                                                                                                                                                                 
  27            Waist                                cm                                                             9N016160100000001                                                                                                                                                                 
  28            Urine glucose                        ‐, ±,+, 2+or over                                              1A990\*\*\*\*00190154                                                                                                                                                             Urinary test strip method
                                                                                                                    1A020\*\*\*\*00190111                                                                                                                                                             Specific health check‐up code
                                                                                                                    \*\*\*\* \[,1288: before breakfast, 1,289: after breakfast, 1,290: before lunch, 1,291: after lunch, 1,292: before supper, 1,293: after supper, 1,299: casual, 1,300: fasting\]   
  29            γ‐GTP                                IU/L                                                           3B090000002327101                                                                                                                                                                 
  30            Diabeteic neuropathy                 Yes, No, Unknown                                               9N046000000000011                                                                                                                                                                 
  31            Regular visit at dental clinic       Yes, No, Unknown                                               9N531000000000011                                                                                                                                                                 
  32            Uric acid                            mg/dL                                                          3C020000002327101                                                                                                                                                                 
  33            Systolic blood pressure at home      mmHg                                                           9A751000000099501                                                                                                                                                                 
  34            Diastolic blood pressure at home     mmHg                                                           9A761000000099501                                                                                                                                                                 
  35            Family history of renal failure      Yes, No, Unknown                                               9N047000000000011                                                                                                                                                                 
  36            Urine protein/Creatinin              g/gCr                                                          1A015000000127128                                                                                                                                                                 
  37            Urine protein/Day                    g/day                                                          1A015000000427126                                                                                                                                                                 
  38            Serum total protein                  g/dL                                                           3A010000002327101                                                                                                                                                                 
  39            BUN                                  mg/dL                                                          3C025000002327201                                                                                                                                                                 
  40            Hemoglobin                           g/dL                                                           2A990000001930953                                                                                                                                                                 
                                                                                                                    2A030000001930901                                                                                                                                                                 Specific health check‐up code
  41            Cystatin C                           mg/L                                                           3C016000002306201                                                                                                                                                                 
  Extra Items   Weight at home                       kg                                                             9N006000000099401                                                                                                                                                                 
  Extra Items   Self‐monitoring blood glucose        mg/dL                                                          3D010\*\*\*\*01899101                                                                                                                                                             
                                                                                                                    \*\*\*\* \[1,288:before breakfast, 1,289: after breakfast, 1,290: before lunch, 1,291: after lunch, 1,292: before supper, 1,293: after supper, 1,299: casual, 1,300: fasting\]    
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Discussion {#jdi13043-sec-0004}
==========

'Big data\' has evolved to incorporate clinical information, and it is expected that a vast amount of diabetes‐related data will be generated. It is therefore important to develop and implement standardized data item sets for diabetes‐related databases. Linking those databases to databases for other chronic diseases should help generate useful, high‐quality data. However, attempts to standardize data item sets have often failed because of an excessive number of items. In our approach, we defined the CIS for each disease and then developed SMISs based on those CISs to minimize the number of items.

Our SMISs have been used in databases for three large disease registry studies (Table [2](#jdi13043-tbl-0002){ref-type="table"}). For example, the Japan Diabetes Comprehensive Database Project Based on an Advanced Electronic Medical Record System (J‐DREAMS), administered by the National Center for Global Health and Medicine and the JDS, used all of our SMIS items for diabetes mellitus[7](#jdi13043-bib-0007){ref-type="ref"}, [8](#jdi13043-bib-0008){ref-type="ref"}. In addition, J‐CDK‐DB[9](#jdi13043-bib-0009){ref-type="ref"}, administered by the JSN, used some of the CKD SMIS items, which can be automatically output from the SS‐MIX2 system[10](#jdi13043-bib-0010){ref-type="ref"}, and the Japan Medical Association Diabetes Database of Clinical Medicine (J‐DOME), administered by the Japan Medical Association to collect clinical information about diabetes, used all of our SMIS items for all four chronic diseases[11](#jdi13043-bib-0011){ref-type="ref"}.

###### 

Outline timetable of implementation using the self‐management item set (SMIS) and the recommended configuration for personal health records (PHRs)

                             Startup   Diabetes SMIS   Hypertension SMIS   Dyslipidemia SMIS   CKD SMIS      Specification for PHR
  -------------------------- --------- --------------- ------------------- ------------------- ------------- -----------------------
  Case Registration cohort                                                                                   
  J‐DREAMS                   2015˜     ◎               --                  --                  --            --
  J‐CKD‐DB                   2015˜     --              --                  --                  ○             --
  J‐DOME                     2016˜     ◎               ◎                   ◎                   ◎             --
  PHR project                                                                                                
  PHR (by MEDIS‐DC)          2016˜     ◎               ◎                   ◎                   ◎             **◎**
  PHR (DialBetics)           2018˜?    ○ (planned)     --                  --                  ○ (planned)   ○ (planned)

◎: full implementation, ○: partial implementation.

John Wiley & Sons, Ltd

We implemented all the SMIS items for the four chronic diseases with detailed specifications for their inclusion in a PHR application that is being developed as part of the MEDIS‐DC project, funded by AMED. We are also conducting verification studies in the cities of Nishinomiya (Hyogo Prefecture), Taku (Saga Prefecture), and Koriyama (Fukushima Prefecture). Finally, another PHR project, 'Expanding and strengthening cooperation of a CKD database and establishment of a comprehensive database,\' initiated in 2017 and also funded by AMED, is using our diabetes‐related SMIS items in the 'DialBetics\' PHR application[12](#jdi13043-bib-0012){ref-type="ref"}.

Conclusions {#jdi13043-sec-0005}
===========

In conclusion, CCCIDM and the CEC established standardized CISs and SMISs for the four chronic diseases. They also developed specifications for implementing these items in PHR applications, such as identifying values for risk stratification, generating alerts using information and communications technology systems, avoiding data input errors, and generating reminders to input the SIMS data. In addition, a table was developed to map the item sets to the JLAC10 codes.
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**Table S1 \|** Recommended configuration for personal health records based on the self‐management item set for healthy people (the basic configuration).

###### 

Click here for additional data file.

###### 

**Table S2 \|** Recommended configuration for personal health records based on the self‐management item set for patients with diabetes mellitus (the diabetic configuration).

###### 

Click here for additional data file.

###### 

**Table S3 \|** Recommended configuration for personal health records based on the self‐management item set for patients with hypertension (the hypertension configuration).

###### 

Click here for additional data file.

###### 

**Table S4 \|** Recommended configuration for personal health records based on the self‐management item set for patients with dyslipidemia (the dyslipidemia configuration).

###### 

Click here for additional data file.

###### 

**Table S5 \|** Recommended configuration for personal health records based on the self‐management item set for patients with chronic kidney disease (the CKD configuration).

###### 

Click here for additional data file.

###### 

**Table S6 \|** Recommended configuration for personal health records based on the self‐management item set for patients with coronary heart disease (the coronary heart disease configuration).

###### 

Click here for additional data file.
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